Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.84 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.84 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.84 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | HTR7 | P34969 | 6/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6092611 | 1.00 | CYP1A2 (0.84) | CYP1A2MAPK1SMN1; SMN2HRH3ALDH1A1 | |
| SCHEMBL26495548 | 1.00 | CYP1A2 (0.84) | CYP1A2MAPK1SMN1; SMN2HRH3ALDH1A1 | |
| SCHEMBL10448990 | 1.00 | CYP1A2 (0.84) | CYP1A2MAPK1SMN1; SMN2HRH3ALDH1A1 | |
| SCHEMBL7364534 | 1.00 | CYP1A2 (0.84) | CYP1A2MAPK1SMN1; SMN2HRH3ALDH1A1 | |
| SCHEMBL26495605 | 1.00 | CYP1A2 (0.84) | CYP1A2MAPK1SMN1; SMN2HRH3ALDH1A1 | |
| SCHEMBL547192 | 0.98 | CYP1A2 (0.88) | CYP1A2MAPK1SMN1; SMN2HRH3ALDH1A1 | |
| SCHEMBL9152244 | 0.98 | CYP1A2 (0.80) | CYP1A2MAPK1SMN1; SMN2HRH3ALDH1A1 | |
| SCHEMBL2639576 | 0.98 | CYP1A2 (0.88) | CYP1A2MAPK1SMN1; SMN2HRH3ALDH1A1 | |
| SCHEMBL9151071 | 0.98 | CYP1A2 (0.80) | CYP1A2MAPK1SMN1; SMN2HRH3ALDH1A1 | |
| SCHEMBL9154341 | 0.98 | CYP1A2 (0.80) | CYP1A2MAPK1SMN1; SMN2HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092078-A1 | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS | DECIDUOUS THERAPEUTICS, INC. (US) | 2025-03-20 | — | — | US | disclosed |
| US-12037357-B2 | Compounds for activating invariant natural killer T-cells and methods of use in eliminating inflammatory senescent cells | DECIDUOUS THERAPEUTICS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037357-B2 | Compounds for activating invariant natural killer T-cells and methods of use in eliminating inflammatory senescent cells | DECIDUOUS THERAPEUTICS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240025936-A1 | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS | DECIDUOUS THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025936-A1 | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS | DECIDUOUS THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | US | disclosed |
| EP-4301374-A1 | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS | Deciduous Therapeutics, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| CN-117222414-A | Compounds for activating constant natural killer T-cells and methods for eliminating inflammatory senescent cells | 脱落性治疗公司 | 2023-12-12 | — | — | CN | disclosed |
| WO-2022187141-A1 | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS | DECIDUOUS THERAPEUTICS (US) | 2022-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037357-B2 | Compounds for activating invariant natural killer T-cells and methods of use in eliminating inflammatory senescent cells | IL2, IL4, PBK | CYP1A2 3917/4885MAPK1 2346/4885SMN1; SMN2 4120/4885 |
| US-20240025936-A1 | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS | IL2, PBK, IL4 | CYP1A2 3908/4885MAPK1 3154/4885SMN1; SMN2 3812/4885 |
| US-20250092078-A1 | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS | IL2, PBK, IL4 | CYP1A2 3832/4885MAPK1 2930/4885SMN1; SMN2 3570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.